search
Back to results

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Primary Purpose

Postsurgical Pain Due to Third Molar Extraction

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
V117957
Ibuprofen
Placebo
Sponsored by
Purdue Pharma LP
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postsurgical Pain Due to Third Molar Extraction focused on measuring Postsurgical pain

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria include:

  • Males aged 18 to 45 years;
  • Females aged 18 to 45 years of nonchildbearing potential;
  • A body mass index of 18 to 30.0 kg/m2, inclusive;
  • Scheduled to undergo outpatient surgical extraction of 2 or more third molars (with at least 1 partial bony mandibular extraction);
  • Experience moderate to severe pain;
  • Use only topical benzocaine, 2% lidocaine with epinephrine, and nitrous oxide as preoperative medication;
  • Are deemed by the investigator to be appropriate candidates for the protocol-specified therapeutic regimen.

Exclusion Criteria include:

  • Are female who are pregnant, lactating or of child-bearing potential, or who have a positive pregnancy test result at screening or check-in;
  • A history or any current conditions that might interfere with drug absorption, distribution, metabolism or excretion;
  • A history of frequent nausea or emesis regardless of etiology;
  • A history of seizures or head trauma with sequelae;
  • A cardiovascular disorder, including hypertension, unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure or active myocardial ischemia;
  • A history of alcohol or substance abuse or addiction;
  • A history of opioid abuse or addiction;
  • A positive urine drug or alcohol test at screening or check-in;
  • A positive urine cotinine test result at screening or check-in, smokes frequently (>1 time per week) or have used tobacco or nicotine substitutes within 1 month before the loading dose of study drug, and/or have an inability to refrain from use of nicotine between check-in and the follow-up visit;
  • Ingest xanthine- or caffeine-containing foods or beverages (eg, coffee, tea, chocolate, and colas) within 24 hours before the loading dose of study drug and for the duration of confinement to the clinical site;
  • Have the presence or history (within 2 years of screening) of bleeding disorder(s) or peptic ulcer disease;
  • Have donated or lost ≥ 500 mL of blood in the 60 days before screening;
  • Use of any medication, other than those that are standard for dental surgery;
  • Have used acetaminophen, ibuprofen, aspirin, or other nonsteroidal anti-inflammatory drugs or any other analgesics (OTC or prescription) within 3 days before surgery; or have used long-acting anesthetics (eg, bupivacaine) or any other medications that may result in prolonged anesthesia, analgesia, or sedation;
  • Have presence of a chronic or acute painful condition, other than the study indication, which could interfere with the assessment of efficacy of the study drug or any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures;
  • Are unsuitable to participate in this study for any other reason, in the opinion of the investigator.

Sites / Locations

  • PPD Dental Pain Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

V117957

Ibuprofen

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Total pain relief 0 to 8 hours after dosing (TOTPAR8)
Time-weighted sum of pain relief scores 0 to 8 hours after dosing

Secondary Outcome Measures

Total Pain Relief 0 - 4 hours after dosing (TOTPAR4)
Total Pain Relief 0 - 6 hours after dosing (TOTPAR6)
Total Pain Relief 0 - 12 hours after dosing (TOTPAR12)
Total Pain Relief 0 - 24 hours after dosing (TOTPAR24)
Pain Relief (PR) over time
Pain intensity difference over time
Sum of pain intensity difference 0 to 4 hours after dosing (SPID4)
Sum of pain intensity difference 0 to 6 hours after dosing (SPID6)
Sum of pain intensity difference 0 to 8 hours after dosing (SPID8)
Sum of pain intensity difference 0 to 12 hours after dosing (SPID12)
Sum of pain intensity difference 0 to 24 hours after dosing (SPID24)
Time to first perceptible PR
Time to meaningful PR
Time to first use of rescue pain medication
Proportion of subjects taking rescue medication by time point
Global assessment of overall satisfaction

Full Information

First Posted
July 12, 2013
Last Updated
December 3, 2013
Sponsor
Purdue Pharma LP
search

1. Study Identification

Unique Protocol Identification Number
NCT01900795
Brief Title
An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction
Official Title
A Phase 2a, Single-Center, Randomized, Double-Blind, Double- Dummy, Placebo- and Active-Controlled Analgesic Study of an Oral Dose of V117957 4.5 mg for the Treatment of Postsurgical Pain Due to Third Molar Extraction
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Terminated
Why Stopped
Terminated early due to administrative reasons not related to safety.
Study Start Date
July 2013 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Purdue Pharma LP

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to assess the analgesic properties of an oral dose of V117957 4.5 mg aqueous suspension in the third molar extraction model

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postsurgical Pain Due to Third Molar Extraction
Keywords
Postsurgical pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
114 (Actual)

8. Arms, Groups, and Interventions

Arm Title
V117957
Arm Type
Experimental
Arm Title
Ibuprofen
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
V117957
Intervention Description
V117957 4.5 mg suspension taken orally after surgery.
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Intervention Description
Ibuprofen 400 mg tablets taken orally after surgery.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo taken orally after surgery.
Primary Outcome Measure Information:
Title
Total pain relief 0 to 8 hours after dosing (TOTPAR8)
Description
Time-weighted sum of pain relief scores 0 to 8 hours after dosing
Time Frame
0 - 8 hours postdose
Secondary Outcome Measure Information:
Title
Total Pain Relief 0 - 4 hours after dosing (TOTPAR4)
Time Frame
Hour 4 postdose
Title
Total Pain Relief 0 - 6 hours after dosing (TOTPAR6)
Time Frame
Hour 6 postdose
Title
Total Pain Relief 0 - 12 hours after dosing (TOTPAR12)
Time Frame
Hour 12 postdose
Title
Total Pain Relief 0 - 24 hours after dosing (TOTPAR24)
Time Frame
Hour 24 postdose
Title
Pain Relief (PR) over time
Time Frame
Up to 24 hours postdose
Title
Pain intensity difference over time
Time Frame
15, 30, 45 , 60, 90 minutes; 2, 3, 4, 4.5, 6, 8, 10, 12 and 24 hours postdose
Title
Sum of pain intensity difference 0 to 4 hours after dosing (SPID4)
Time Frame
Hour 4 postdose
Title
Sum of pain intensity difference 0 to 6 hours after dosing (SPID6)
Time Frame
Hour 6 postdose
Title
Sum of pain intensity difference 0 to 8 hours after dosing (SPID8)
Time Frame
Hour 8 postdose
Title
Sum of pain intensity difference 0 to 12 hours after dosing (SPID12)
Time Frame
Hour 12 postdose
Title
Sum of pain intensity difference 0 to 24 hours after dosing (SPID24)
Time Frame
Hour 24 postdose
Title
Time to first perceptible PR
Time Frame
Up to 24 hours postdose
Title
Time to meaningful PR
Time Frame
Up to 24 hours postdose
Title
Time to first use of rescue pain medication
Time Frame
Up to 24 hours postdose
Title
Proportion of subjects taking rescue medication by time point
Time Frame
Up to 24 hours postdose
Title
Global assessment of overall satisfaction
Time Frame
Hour 24 postdose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria include: Males aged 18 to 45 years; Females aged 18 to 45 years of nonchildbearing potential; A body mass index of 18 to 30.0 kg/m2, inclusive; Scheduled to undergo outpatient surgical extraction of 2 or more third molars (with at least 1 partial bony mandibular extraction); Experience moderate to severe pain; Use only topical benzocaine, 2% lidocaine with epinephrine, and nitrous oxide as preoperative medication; Are deemed by the investigator to be appropriate candidates for the protocol-specified therapeutic regimen. Exclusion Criteria include: Are female who are pregnant, lactating or of child-bearing potential, or who have a positive pregnancy test result at screening or check-in; A history or any current conditions that might interfere with drug absorption, distribution, metabolism or excretion; A history of frequent nausea or emesis regardless of etiology; A history of seizures or head trauma with sequelae; A cardiovascular disorder, including hypertension, unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure or active myocardial ischemia; A history of alcohol or substance abuse or addiction; A history of opioid abuse or addiction; A positive urine drug or alcohol test at screening or check-in; A positive urine cotinine test result at screening or check-in, smokes frequently (>1 time per week) or have used tobacco or nicotine substitutes within 1 month before the loading dose of study drug, and/or have an inability to refrain from use of nicotine between check-in and the follow-up visit; Ingest xanthine- or caffeine-containing foods or beverages (eg, coffee, tea, chocolate, and colas) within 24 hours before the loading dose of study drug and for the duration of confinement to the clinical site; Have the presence or history (within 2 years of screening) of bleeding disorder(s) or peptic ulcer disease; Have donated or lost ≥ 500 mL of blood in the 60 days before screening; Use of any medication, other than those that are standard for dental surgery; Have used acetaminophen, ibuprofen, aspirin, or other nonsteroidal anti-inflammatory drugs or any other analgesics (OTC or prescription) within 3 days before surgery; or have used long-acting anesthetics (eg, bupivacaine) or any other medications that may result in prolonged anesthesia, analgesia, or sedation; Have presence of a chronic or acute painful condition, other than the study indication, which could interfere with the assessment of efficacy of the study drug or any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures; Are unsuitable to participate in this study for any other reason, in the opinion of the investigator.
Facility Information:
Facility Name
PPD Dental Pain Clinic
City
Austin
State/Province
Texas
ZIP/Postal Code
78744
Country
United States

12. IPD Sharing Statement

Learn more about this trial

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

We'll reach out to this number within 24 hrs